News

Avenda Health’s Unfold AI™ Shown to More Precisely Predict Extraprostatic Extension Risk in Prostate Cancer Patients, Surpassing Conventional Methodology

Avenda Health Announces First Commercial Use of Unfold AI on Prostate Cancer Patients in the U.S.

Prostate Cancer Technology Startup, Avenda Health, Partnering with BioscienceLA to Establish New Life Sciences Innovation Hub in U.S.

A Novel AI – Derived Metric Identifies Favorable Candidates of Focal Therapy of Prostate Cancer and Accurately Predicts Treatment Margin Efficacy

Automatic Ablation Site Selection for Focal Therapy

Defining Prostate Cancer Focal Therapy Treatment Margins with a Machine Learning Model: Improvement Upon Hemi-Gland Ablation

Unfold AI Clinical Validation Efforts

First AI-Powered Precision Oncology Platform for Prostate Cancer Care, iQuest Receives FDA Clearance

December 13, 2022